Opioid Use and Back Pain Statistics (2026): What the Evidence Really Shows
Opioids became the most commonly prescribed drug class associated with low back pain in the U.S., yet systematic reviews find only weak, short-term evidence that they help chronic back pain, and real risks of dependence. That gap is why national guidelines now favor non-opioid and interventional approaches first.
- Opioids became the most commonly prescribed drug class associated with low back pain in the U.S., and more than half of regular opioid users report back pain.
- Opioid prescribing for back pain varies widely by setting, from about 3% to 66%, per a systematic review.
- U.S. and Canadian opioid prescribing rates have run 2 to 3 times higher than in most European countries.
- For chronic low back pain, evidence of efficacy is short-term and low quality; average pain relief across chronic non-cancer pain is about 30%, with unclear functional benefit.
- Aberrant medication-taking behaviors occur in up to 24% of chronic back pain patients on opioids; abuse/dependence risk rises with dose, from 0.7% (low dose) to 6.1% (high dose).
- The CDC's 2022 guideline states nonopioid and nonpharmacologic therapies are preferred for chronic pain.
What's in This Report
1How Common Opioids Are for Back Pain
Back pain and opioids have been deeply intertwined in American medicine. As prescribing climbed over the past two decades, opioids became the most commonly prescribed drug class associated with low back pain in the United States, and more than half of regular opioid users report back pain. The scale of use, and how much it varies, is striking.
Prevalence also depends on how you count. A meta-analysis of chronic non-cancer pain found long-term opioid use in about 5.8% of people with chronic low back pain and around 20.5% of patients with musculoskeletal pain overall. Whatever the exact figure, the pattern is clear: opioids have been a default response to back pain far more often than the evidence supports.
Source: BMJ, Opioids for low back pain (PMC) | Annals of Internal Medicine systematic review
Explore interventional pain treatments2What the Evidence Says About Effectiveness
Here is the disconnect at the heart of the issue: despite how widely opioids have been prescribed for back pain, the evidence that they work, particularly for chronic pain and over the long term, is thin. Systematic reviews consistently reach the same cautious conclusion.
The Cochrane review of opioids for chronic low back pain found only very-low-to-moderate-quality evidence of short-term efficacy for both pain and function compared with placebo, with high dropout rates and short trial durations limiting confidence. A separate analysis noted that opioids do not appear to speed return to work in injured workers or improve functional outcomes of acute back pain in primary care.
The evidence doesn't support that. For chronic low back pain, systematic reviews find only short-term, low-quality evidence of modest relief, roughly 30% on average across chronic pain, with unclear benefit for function and essentially no long-term data. Meanwhile the risks accumulate over time. "Strong medication" is not the same as "effective long-term treatment," which is exactly why guidelines steer toward other options first.
Source: Cochrane Review, opioids for chronic low back pain | BMJ (PMC)
See conservative, non-opioid care options3The Risk Side of the Ledger
While the benefits for chronic back pain are modest and short-lived, the risks of long-term opioid use are well documented and, importantly, dose-dependent. This asymmetry, limited benefit against real risk, is what reshaped clinical practice.
An NIH systematic review found that compared with no opioid prescription, long-term opioid therapy was associated with a sharply higher risk of an opioid abuse or dependence diagnosis, with adjusted odds ratios rising from about 15 for low-dose therapy to over 120 for high-dose therapy. Common short-term side effects, constipation, nausea, sedation, and increased fall and fracture risk, add to the burden even before dependence becomes a concern.
Placing two findings side by side captures why practice changed. Opioids deliver roughly 30% short-term pain relief for chronic pain, with unclear functional benefit and no reliable long-term efficacy data, while the risk of abuse or dependence can rise more than a hundredfold at high doses versus no opioids. A treatment whose benefit plateaus while its risk climbs with dose and duration is, by definition, one to use sparingly and briefly, if at all, for chronic back pain. That is the evidence-based case for identifying and treating the source of the pain instead. Calculation and interpretation original to Desert Spine and Pain, based on BMJ (PMC) and NIH Pathways to Prevention data.
Source: NIH Pathways to Prevention systematic review (Annals) | BMJ (PMC)
Learn about RFA and spinal cord stimulation4What the Guidelines Recommend
The shift in the evidence is reflected directly in national guidance. The CDC's 2022 Clinical Practice Guideline for Prescribing Opioids for Pain, which updated the 2016 guideline and expanded to cover acute, subacute, and chronic pain, is explicit about sequencing.
The guideline advises that clinicians should consider opioid therapy only if the expected benefits for both pain and function are anticipated to outweigh the risks. It also stresses individualized, patient-centered decisions, cautioning against rigid dose thresholds and abrupt tapering, which can cause their own harms. In short: opioids are not banned, but for chronic back pain they are no longer the default, and the emphasis is on treating pain at its source.
Source: CDC Clinical Practice Guideline for Prescribing Opioids for Pain, 2022 (MMWR)
Explore spine surgery options5Evidence-Based Alternatives
If opioids are not the answer for most chronic back pain, what is? The guideline-preferred path starts with nonopioid medication and active rehabilitation, and, when appropriate, moves to interventional procedures that target the pain source directly, and to surgery when a structural cause is identified. This "least invasive effective treatment first" ladder is exactly how a modern spine and pain practice is designed to work.
Desert Spine and Pain is built around this evidence-based, least-invasive-first philosophy. Led by Dr. David L. Greenwald, MD, FACS, who is both a spine surgeon and a neurosurgeon, the practice works to identify the true source of a patient's pain and treat it directly, through conservative care and a full range of interventional pain procedures, including epidural steroid injections, nerve blocks, radiofrequency ablation, and spinal cord stimulation, and through minimally invasive surgery when a structural problem calls for it. The goal is durable relief and restored function, framed as reported ranges for appropriately selected patients rather than guarantees, not indefinite reliance on medication.
For patients whose back pain follows an accident, and the personal injury attorneys who represent them, this approach also supports clear documentation of an evidence-based treatment path. For the broader cost picture of chronic back pain, see our report on back pain economic cost statistics.
If you have been managing back pain with opioids and feel stuck, you are not alone, and you have options. Guideline-preferred, non-opioid approaches, from rehabilitation to targeted interventional procedures to surgery when warranted, aim to treat the cause of pain rather than mask it. Talk with a qualified spine and pain specialist about an individualized plan. This article is general information, not medical advice, and is not a recommendation to start, stop, or change any medication; decisions about opioids should be made with your prescribing clinician.
Source: CDC Clinical Practice Guideline, 2022 (MMWR) | Cochrane Review
Get a consultation: (602) 566-9500Opioid Use and Back Pain Statistics: Summary Table (2026)
| Statistic | Figure | Source | Year |
|---|---|---|---|
| Regular opioid users who report back pain | >50% | BMJ (PMC/NIH) | 2015 |
| Opioid prescribing range for back pain, by setting | 3%-66% | Annals of Internal Medicine | 2007 |
| U.S./Canada prescribing vs. Europe | 2-3x higher | BMJ (PMC/NIH) | 2015 |
| Long-term opioid use, chronic low back pain | ~5.8% | Meta-analysis (PMC) | 2020 |
| Opioid use, musculoskeletal pain patients | ~20.5% | Meta-analysis (PMC) | 2020 |
| Average pain relief, chronic non-cancer pain | ~30% | BMJ (PMC/NIH) | 2015 |
| Typical RCT duration behind the evidence | ≤4 months | BMJ / Cochrane | 2015-2023 |
| Aberrant medication-taking behaviors | Up to 24% | Annals of Internal Medicine | 2007 |
| Abuse/dependence, low-dose therapy | 0.7% | NIH Pathways review (Annals) | 2015 |
| Abuse/dependence, high-dose therapy | 6.1% | NIH Pathways review (Annals) | 2015 |
| Adjusted odds ratio for abuse/dependence, high dose | >120x vs. no opioids | NIH Pathways review (Annals) | 2015 |
| Cochrane evidence quality, CLBP efficacy | Very low to moderate (short-term) | Cochrane Review | 2013/2025 |
| CDC position, chronic pain first-line | Nonopioid/nonpharmacologic preferred | CDC Guideline | 2022 |
| CDC definition of chronic pain | >3 months | CDC Guideline | 2022 |
| Effect on return to work (injured workers) | No clear benefit | BMJ (PMC/NIH) | 2015 |
| RFA relief duration (alternative) | 6-18 months | Interventional pain literature | Cited |
| Spinal cord stimulation relief (alternative) | Can last years | Interventional pain literature | Cited |
Frequently Asked Questions
How common are opioids for back pain?
Do opioids work for chronic back pain?
What are the risks of taking opioids for back pain?
What are the alternatives to opioids for back pain?
Does the CDC recommend opioids for back pain?
Methodology & Sources
How we compiled this report
All figures are drawn from Tier 1 primary sources: the CDC, Cochrane systematic reviews, and peer-reviewed research indexed in PMC/NIH. Prescribing prevalence, efficacy magnitude, and cross-country comparisons come from the BMJ review "Opioids for low back pain" and a systematic review in the Annals of Internal Medicine. Efficacy and evidence-quality assessments come from the Cochrane Review of opioids for chronic low back pain. Dose-dependent abuse and dependence figures come from the NIH Pathways to Prevention systematic review. Guideline positions come directly from the CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (MMWR).
Some underlying studies span a range of years and settings, and prevalence figures vary widely by population and methodology, so they are presented as ranges with their original framing. This report describes population-level evidence and guideline positions; it is not medical advice and is not a recommendation to start, stop, change, or taper any medication. Decisions about opioid therapy should be made individually with a qualified prescribing clinician. Figures are rounded.
- CDC, "Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022," MMWR
- Deyo RA, et al. "Opioids for low back pain," BMJ (PMC/NIH)
- Martell BA, et al. "Systematic Review: Opioid Treatment for Chronic Back Pain," Annals of Internal Medicine
- Cochrane Review, "Opioids for the treatment of chronic low back pain"
- Chou R, et al. NIH Pathways to Prevention systematic review, Annals of Internal Medicine
You are welcome to cite these statistics with attribution to the original primary sources named above (the CDC, BMJ, Annals of Internal Medicine, Cochrane, and NIH). When referencing the Desert Spine and Pain Analysis, please attribute the calculation to Desert Spine and Pain. This article is general information and not medical advice.
